Copperwynd Financial LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

Copperwynd Financial LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 33.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,005 shares of the company’s stock after purchasing an additional 1,263 shares during the quarter. Copperwynd Financial LLC’s holdings in Zoetis were worth $901,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Webster Bank N. A. grew its stake in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management acquired a new stake in Zoetis in the 4th quarter valued at $40,000. LRI Investments LLC purchased a new position in Zoetis in the first quarter valued at about $43,000. Hazlett Burt & Watson Inc. lifted its stake in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC purchased a new stake in shares of Zoetis in the second quarter worth about $49,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $194.81 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $88.89 billion, a price-to-earnings ratio of 37.54, a price-to-earnings-growth ratio of 2.97 and a beta of 0.88. The business has a 50 day simple moving average of $186.04 and a 200 day simple moving average of $174.79.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company earned $1.41 earnings per share. On average, equities research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Stifel Nicolaus boosted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.